Tesla mRNA microfactories

[Buckminster]

https://twitter.com/elonmusk/status/1278579417967665152

Elon announced that Grohmann will be be selling microfactories (that manufacture mRNA) to the like of CureVac that use mRNA as a vaccine (that doesn't require refrigeration).

Bill and Melinda Gates foundation have invested in CureVac.

 

[Buckminster]

More reason to be happy with Tesla stock

Bill and Melinda Gates-backed coronavirus vaccine maker soars in Wall Street debut - CNN

"
The race for a successful coronavirus vaccine is heating up in labs around the world — and on Wall Street. Germany's CureVac, a biotech with the backing of the Bill & Melinda Gates Foundation, more than tripled in its first day of trading Friday.

CureVac priced its initial public offering at $16 a share. The stock soared nearly 250%, to just below $56, by the end of the day."

"CureVac also has another big name in its roster of partners: the firm is working on technology with Elon Musk's electric car giant Tesla (TSLA). The company has had a development and intellectual property agreement with Tesla since November 2015, according to its regulatory filings with the Securities and Exchange Commission.
Musk tweeted last month that Tesla's German Grohmann division is helping build molecule printers for CureVac — a "side project" that may work with other drug companies."

 

[Buckminster]

Elon remains positive:
https://twitter.com/elonmusk/status/1325938304810967042
Interesting that Pfizer used mRNA also - clearly the way to go.

 

[Buckminster]

Yahoo is now a part of Verizon Media
Curevac SP up 8% on this news today. Fridge storage only confirmed. Q3 2021 approval was later than I was expecting though.

 

[replicant]

CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy

German biotech CureVac NV (5CV.DE) said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.

www.reuters.com